financetom
Business
financetom
/
Business
/
Carl Icahn welcomes dismissal of Icahn Enterprises lawsuit, not selling shares
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Carl Icahn welcomes dismissal of Icahn Enterprises lawsuit, not selling shares
Sep 16, 2024 12:38 PM

Sept 16 (Reuters) - Carl Icahn said on Monday he was

pleased a federal judge dismissed a lawsuit accusing the

billionaire of defrauding shareholders of his investment company

Icahn Enterprises ( IEP ) so he could obtain large amounts of

personal loans.

The lawsuit followed a May 2023 report by the short-selling

firm Hindenburg Research that questioned whether Icahn's company

inflated its share price by paying out excessive shareholder

dividends, enabling Icahn's borrowing. Hindenburg also accused

Icahn of overseeing a "Ponzi-like economic structure."

Icahn owns 85% of his namesake company, and has lost many

billions of dollars because its stock price has fallen by more

than three-quarters since the Hindenburg report, touching a more

than 20-year low last week.

But in a decision on Friday, U.S. District Judge K. Michael

Moore in Miami said Icahn Enterprises ( IEP ) sufficiently disclosed its

risks to shareholders. The judge also said evidence suggested

that Icahn "believed in the long-term value" of his company.

Icahn Enterprises ( IEP ) called the lawsuit "meritless," and Icahn

said in a statement: "We are pleased that the spurious claims of

various unscrupulous characters, working together in a

coordinated and clandestine network, have been debunked."

The 88-year-old Icahn also said he is "absolutely not

selling" Icahn Enterprises ( IEP ) shares, denying contrary claims he

said were in media reports.

Lawyers for the shareholders did not respond to requests for

comment on Friday after the decision, and to further requests

for comment on Monday.

Last month, Icahn and his company agreed without admitting

wrongdoing to pay $2 million in civil fines to settle U.S.

Securities and Exchange Commission charges he did not disclose

pledging large quantities of shares as collateral for his loans.

Icahn's fortune far exceeded $10 billion for many years, and

is now $4.9 billion according to Forbes magazine.

The case is Kosowsky v Icahn Enterprises LP ( IEP ) et al, U.S.

District Court, Southern District of Florida, No. 23-21773.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Wingstop Q3 system-wide sales rise 10%, helped by new restaurants
Nov 4, 2025
Overview * Wingstop ( WING ) fiscal Q3 system-wide sales rise 10% to $1.4 bln * Adjusted EBITDA for fiscal Q3 grows 18.6% to $63.7 mln, highest quarter on record * Company opened 114 net new restaurants, achieving 19.3% net new unit growth Outlook * Wingstop ( WING ) revises 2025 domestic same store sales growth to decline 3%-4% *...
Hillman Q3 net sales rise 8%, beat estimates
Hillman Q3 net sales rise 8%, beat estimates
Nov 4, 2025
Overview * Hillman Q3 2025 net sales rise 8% to record $424.9 mln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, reaching $0.22 per share * Company repurchased 325.6 thousand shares, totaling $3.2 mln Outlook * Hillman maintains FY 2025 net sales guidance at $1.535 to $1.575 bln * Company raises FY 2025 adjusted EBITDA guidance to...
Nuvectis Pharma Q3 net loss widens
Nuvectis Pharma Q3 net loss widens
Nov 4, 2025
Overview * Nuvectis Q3 net loss widens to $7.5 mln, driven by milestone and study costs * Cash position improves to $35.4 mln, supported by public offering and ATM facility * NXP900 Phase 1b program initiated, showcasing therapeutic potential in advanced cancers Outlook * Cash runway expected to support operations into 3Q-2027 Result Drivers * Research and development expenses were...
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
BRIEF-Evoke Pharma Enters Into Definitive Agreement To Be Acquired By QOL Medical
Nov 4, 2025
Nov 4 (Reuters) - Evoke Pharma Inc ( EVOK ): * EVOKE PHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY QOL MEDICAL * EVOKE PHARMA INC ( EVOK ): PROPOSED DEAL FOR FOR $11.00 PER SHARE IN CASH AT CLOSING Source text: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved